Pneumococcal Conjugate Vaccine

India has a strong infrastructure with centers of excellence in biomedical sciences and talented scientists and engineers.

Hilleman Laboratories aims to be recognized as the Center of Excellence for early-stage development of vaccines by bringing together the scientific prowess of global partners and funders to benefit the world’s poorest.

Hilleman labotaries located at Jamia Hamdard university in New Delhi has its prime focus on contributing to the field of vaccine research and development. Its state-of-the-art GLP (Good Laboratory Practice) compliant R&D facility that provides access access to new methods of discovery and innovation and technologies to explore promising research concepts for improving immunization conditions in developing countries.

Headquartered in India, Hilleman Laboratories aims to prudently utilize the advantages India offers in science, the vaccine industry and public health policy to develop and mature its R&D pipeline and also contribute to the field of vaccine research & development in India. India also has a strong pharmaceutical and biotech sector with capacity for large-scale manufacturing through DCVMs who provide manufacturing and distribution infrastructure in Asia and sub-Saharan Africa, WHO-approved vaccine development companies and a strong regulatory environment.